In this episode, we sit down with Dr. Abdelrahman Mahmoud, CEO & Founder of CellRewire, to explore a bold new vision for medicine: predictive and reprogrammable biology. What if AI could read the language of our cells, predict disease years before it emerges, and even reprogram cells back to a healthy state? We dive into CellRewire's groundbreaking Cell-DRL agent (Cellular Deep Reinforcement Learning), how it generates novel reprogramming therapies, and how AI can design targeted gene programs and interventions to guide diseased cells back to health.Whether you're into biotech, AI, or the future of medicine, this one's for you.Learn more about CellRewire: https://www.cellrewire.comLearn more about Transcribed: https://transcribedpod.com

In this episode we sit down with the CEO of PEPperPRINT Volker Stadler to explore how affordable peptide micro-arrays change the landscape of vaccine development, biotech research and more.

Find us on all platforms:https://linktr.ee/transcribed_podcast#innovation

#peptides #PEPperPRINT #biotech #transcribed #transcribed volker stadler #volker #stadler #Volker Stadler #podcast #biotech podcast #students #antibody #research #startup #pharma

In this episode, we sit down with Dr. Axel Schumacher to cover topics such as ageing, epigenetics and AI.

In this episode of our biotech podcast, we sit down with Patrick Most – biotech entrepreneur, founder of Aavigen, and professor of cardiology in Heidelberg University, Germany. Together, we explore his journey, insights into gene therapy, and how it will change the therapeutic landscape.Hosted by Meronn and Pierre00:00:00 Intro00:01:40 Why gene therapy?00:03:20 From Academia to Biotech00:12:20 pitching a startup00:13:30 pitfalls when translating academic findings00:17:00 Accessibility of gene therapy00:19:40 Viruses to cure diseases???00:28:00 AI in gene therapy00:30:40 Business model00:34:05 Clearing misconceptions00:36:10 Patience as a biotech founder00:43:10 Day to day as professor and biotech founder00:45:00 Spinning out early or later?00:47:00 The role of a CEO00:51:35 Choosing Co-Founders00:54:10 Corona00:56:00 Biotech winter00:58:30 Networking01:01:00 How to get started as a student01:02:45 Impact of being a CEO on professor and vice versa01:05:00 US vs. Germany01:08:00 Doing something differently?01:10:03 When will Gene therapy cure heart disease?01:13:00 Conclusion#genetherapy #biotechnology #PatrickMost #transcribed #AAV #virus #research #professor #Heidelberg #innovation

In this episode of our biotech podcast, we sit down with Christian Tidona – biotech entrepreneur, founder of BioMed X, and a key figure shaping the future of life sciences in Germany. Together, we explore his journey, insights into biotech innovation, and the intersection of science, business, and impact.Hosted by Meronn and PierreTimecodes:00:00 - From Lab to Venture: Christian Tidona’s Origin Story03:10 - Failing and perseverence05:00 - Choosing Co‑Founders: Trust Over Superstars06:15 - Mentors10:00 - Underestimating founding a company11:25 - Business plan competitions13:25 - Preparing to be lucky15:00 - Trusting the right people17:46 - Growing a company20:00 - VC vs Privately owned25:00 - Scaling: Shifts from 5 to 50+ Employees26:30 - Networking30:00 - Work–Life Integration for Founders31:00 - Academia vs Industry vs Entrepreneurship33:10 - Typical day of an entrepreneur?35:00 - Crisis Playbook: When Experiments (or Equipment) don’t work35:30 - 80% focus 20% exploration37:20 - Do it all over again38:30 - Development of the Heidelberg region40:00 - BioRegio to BioMed X: Building Heidelberg’s Biotech Hub42:30 - Allergic to mediocrity44:55 - Spotting High‑Potential46:10 - Long-term perspectiveSubscribe for more conversations with pioneers in biotech and beyond.#Biotech #ChristianTidona #BioMedX #SciencePodcast #Startup